secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vivani Medical, Inc. (VANI)
CIK:        0001266806
Form:       8-K
Filed at:   2026-05-13T20:25:45+00:00
Accession:  0001753926-26-000854
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vivani Medical reports Q1 2026 net loss of $6.8M; SLIM-1 trial on track for mid-2026
--------------------------------------------------------------------------------

- Net loss of $6.8M in Q1 2026, up from $6.3M in Q1 2025; R&D expense $4.4M (+4% YoY).
- Cash, equivalents and capital commitments of $28M expected to fund operations through first half of 2027.
- Raised $9.7M in financing in Q1 2026, including $2.2M from a registered direct offering.
- SLIM-1 Phase 1 trial of NPM-139 semaglutide implant to start mid-2026; top-line results by end of 2026.
- Cortigent spin-off or IPO under consideration; S-1 amendment filed May 13, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1266806/000175392626000854/0001753926-26-000854-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1266806/000175392626000854/vani-20260513.htm
  HTML page:      https://secwatch.observer/filing/0001753926-26-000854

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer